We’re pleased to share a video interview with our CEO, Dr James Garner on Proactive Investors following the recent commencement of the GBM AGILE study, which will serve as the pivotal study for registration of our lead candidate, paxalisib.
In the interview, Dr Garner discusses:
- How one of the key attributes of GBM AGILE is the adaptive statistical approach its employs, which means the study only recruits the number of patients needed to get a result and is therefore very efficient in terms of time and cost;
- Kazia’s strategy for commercial partnerships for paxalisib;
- Our recent capital raising; and
- How CY2021 will be a "year of data" for Kazia with a number of key milestones expected over the coming 12 months.
You can watch the video here: